PHKA2 and neoplasm: As a novel naphthoquinone derivative based on shikonin modification, the PKM2 inhibitor exhibits robust inhibitory capabilities against the tumor cell-specific M2 subtype of PyK and shows significantly enhanced inhibition compared to its precursor, shikonin [35].